LONDON (ShareCast) - Sell shares of BG Group, Danny Fortson advised in the Sunday Times. Credit Suisse analysts have questioned whether the gas producer's big Australian operation will open on time and have said BG's estimates for its Brazilian oil fields are bigger than those of Petrobas, which leads the development. If the Australian project is delayed, BG could suffer penalty payments for contracts agreed. In the meantime, BG has no chief executive. Fortson concluded he was with Credit Suisse on BG.
Sell shares of Genel Energy, Questor recommended in the Sunday Telegraph. The Kurdistan-focused oil explorer, headed by former BP boss Tony Hayward, withdrew staff from operations after terrorists invaded Iraq. Falling oil prices since June will hit profits. The company now has a new pipeline that allows it to bypass Baghdad but profits and cash are falling and the company has high running costs. The shares are down 17% since Questor's recommendation almost a year ago and are too risky.

Buy shares of Palace Capital, Midas recommended in the Mail on Sunday. The AIM-listed company's bosses have a century of property market experience between them and are building a commercial real estate firm in markets outside London. Since listing in 2010, Palace has bought companies or portfolios, not individual buildings. Recent acquisitions are performing well and Palace has plans to renovate properties to bring in more revenue. Profits and dividends are expected to rise strongly in the year to April 2015.

Green Dragon Gas's shares have risen since Questor recommended the China-focused gas producer but now is the time to sell, the Sunday Telegraph tipster said. Demand for gas in China will be strong because the country wants to reduce pollution in its cities. Green Dragon's future is now more predictable after the Government handed back ownership of its oil well. But the shares have gained 65% since Questor's original tip last December. With China's economy slowing and oil prices falling, it's time to take profits.

Immupharma is a binary bet, Danny Fortson suggested in the Sunday Times. The drug company has struggled to get its treatment for Lupuzor from the lab to the millions who suffer from the autoimmune disease but it will soon start the last stage of clinical trials. The company also has an anonymous backer it says will finance the testing programme. But blockbuster drugs often fail at the last stage and the loss-making company is risky. If all goes well the shares will soar. If not, investors will lose out.

Please note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.

Sean Farrell

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE